Talk:Budesonide/formoterol

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Budesonide/formoterol.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Insomnia

Why do we list "Insomnia" under common side-effects and "Difficulty to fall asleep" under uncommon side-effects? --Guy Macon (talk) 23:09, 17 August 2012 (UTC)[reply]

Cost

What does the drug cost? Is there any outlook on price changes in the foreseeable future? Thanks --Lbeaumont (talk) 00:50, 25 September 2015 (UTC)[reply]

Issues

Secondary sources

I have gone through and removed a mass of primary sources once and left requests for the accounts in question to use secondary sources. Now we have a whole new group of accounts adding the same primary sources again.

Primary source Beasley, Richard; Holliday, Mark; Reddel, Helen K.; Braithwaite, Irene; Ebmeier, Stefan; Hancox, Robert J.; Harrison, Tim; Houghton, Claire; Oldfield, Karen; Papi, Alberto; Pavord, Ian D. (2019-05-23). "Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma". New England Journal of Medicine. 380 (21): 2020–2030. doi:10.1056/NEJMoa1901963. ISSN 0028-4793.

Primary source O’Byrne, Paul M.; FitzGerald, J. Mark; Bateman, Eric D.; Barnes, Peter J.; Zhong, Nanshan; Keen, Christina; Jorup, Carin; Lamarca, Rosa; Ivanov, Stefan; Reddel, Helen K. (2018-05-17). "Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma". New England Journal of Medicine. 378 (20): 1865–1876. doi:10.1056/NEJMoa1715274. ISSN 0028-4793.

Primary source Bateman, Eric D.; Reddel, Helen K.; O’Byrne, Paul M.; Barnes, Peter J.; Zhong, Nanshan; Keen, Christina; Jorup, Carin; Lamarca, Rosa; Siwek-Posluszna, Agnieszka; FitzGerald, J. Mark (2018-05-16). "As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma". New England Journal of Medicine. doi:10.1056/NEJMoa1715275.

Primary source Balanag, V. M.; Yunus, F.; Yang, P. -C.; Jorup, C. (2006-04-01). "Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma". Pulmonary Pharmacology & Therapeutics. 19 (2): 139–147. doi:10.1016/j.pupt.2005.04.009. ISSN 1094-5539.

There are secondary sources on this topic.

Doc James (talk · contribs · email) 05:52, 11 May 2020 (UTC)[reply]

This uses a primary source to refuse a secondary one

"There were previous concerns that the use of Budesonide/Formoterol increases the risk of Influenza, however this has been disproven in later studies"

Primary source Sharafkhaneh, Amir; Southard, John G.; Goldman, Mitchell; Uryniak, Tom; Martin, Ubaldo J. (2012-02). "Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized study". Respiratory Medicine. 106 (2): 257–268. doi:10.1016/j.rmed.2011.07.020. ISSN 0954-6111. {{cite journal}}: Check date values in: |date= (help)

Secondary source Dong, Yaa-Hui; Chang, Chia-Hsuin; Wu, Fe-Lin Lin; Shen, Li-Jiuan; Calverley, Peter M.A.; Löfdahl, Claes-Göran; Lai, Mei-Shu; Mahler, Donald A. (2014-06). "Use of Inhaled Corticosteroids in Patients With COPD and the Risk of TB and Influenza". Chest. 145 (6): 1286–1297. doi:10.1378/chest.13-2137. ISSN 0012-3692. {{cite journal}}: Check date values in: |date= (help) ."

And the secondary source is even newer than the primary one. Also User:Erikajmarsh why did you remove the product monograph? Doc James (talk · contribs · email) 06:01, 11 May 2020 (UTC)[reply]

Other concerns

The product monograph states "is NOT indicated for the relief of acute bronchospasm."

We summarized this as "It is not recommended for sudden worsening or treatment of active bronchospasm."[1]

User:Maddiek12 Changed it to the exact opposite "The use of Symbicort has been demonstrated to be safe in both maintenance and as needed treatment of asthma and acute bronchospasm."

Doc James (talk · contribs · email) 05:56, 11 May 2020 (UTC)[reply]

I have updated that text based on a secondary source to "The product monograph does not support its use for sudden worsening or treatment of active bronchospasm.^[1] However, a 2020 review of the literature does support such use.^[2]"

Doc James (talk · contribs · email) 06:21, 11 May 2020 (UTC)[reply]

This edit[2]

User:Nundah123 you:

Primary source Tegethoff, Marion; Greene, Naomi; Olsen, Jørn; Schaffner, Emmanuel; Meinlschmidt, Gunther (2012-03). "Inhaled Glucocorticoids during Pregnancy and Offspring Pediatric Diseases: A National Cohort Study". American Journal of Respiratory and Critical Care Medicine. 185 (5): 557–563. doi:10.1164/rccm.201108-1482OC. ISSN 1073-449X. {{cite journal}}: Check date values in: |date= (help)

This source which does not mention formoterol and is a primary source Breton, Marie-Claude; Beauchesne, Marie-France; Lemière, Catherine; Rey, Évelyne; Forget, Amélie; Blais, Lucie (2010-10). "Risk of perinatal mortality associated with inhaled corticosteroid use for the treatment of asthma during pregnancy". Journal of Allergy and Clinical Immunology. 126 (4): 772–777.e2. doi:10.1016/j.jaci.2010.08.018. ISSN 0091-6749. {{cite journal}}: Check date values in: |date= (help)

This primary source https://www.jacionline.org/article/S0091-6749(14)01105-1/fulltext

We already had it sufficient supported by a secondary source. No need for the primary sources. Doc James (talk · contribs · email) 06:07, 11 May 2020 (UTC)[reply]

And this edit[3]

User:Megan.sharkey11 this[4] is a primary source from 2016. As is this.[5]

We already state that the concerns were removed in 2017 and no need for the primary sources. Doc James (talk · contribs · email) 06:33, 11 May 2020 (UTC)[reply]

Well this is a review[6] it is a little old and it is unclear what you are using it to try to support? Doc James (talk · contribs · email) 06:35, 11 May 2020 (UTC)[reply]

References

^ Cite error: The named reference Symbicort FDA label was invoked but never defined (see the help page).
^ Jenkins, CR; Bateman, ED; Sears, MR; O'Byrne, PM (31 March 2020). "What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?". Respirology (Carlton, Vic.). doi:10.1111/resp.13804. PMID 32237004.

Introduction: Side Effects

Influenza was erroneously listed as a side-effect in the introduction. Medication cannot cause the spontaneous incidence of influenza virus as a side effect. I have updated this with a list of the side effects acknowledged as common side effects and provided references. SquattyRoo (talk) 18:33, 2 July 2021 (UTC)[reply]

References

A Commons file used on this page or its Wikidata item has been nominated for deletion

The following Wikimedia Commons file used on this page or its Wikidata item has been nominated for deletion:

Symbicort with a dose indicator atop (budesonide-formoterol).jpg

Participate in the deletion discussion at the nomination page. —Community Tech bot (talk) 20:51, 31 December 2021 (UTC)[reply]

[Symbicort_FDA_label-1] Cite error: The named reference Symbicort FDA label was invoked but never defined (see the help page).

[2] Jenkins, CR; Bateman, ED; Sears, MR; O'Byrne, PM (31 March 2020). "What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?". Respirology (Carlton, Vic.). doi:10.1111/resp.13804. PMID 32237004.

[1]

[2]